Inventiva S.A. - American Depos (NASDAQ:IVA)
| Market Cap | 175.18M-43.9% |
| Revenue (ttm) | 4.48M-64.6% |
| Net Income | -352.82M-226.1% |
| EPS | -1.90-45.1% |
| Shares Out | 51.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,996,983 |
| Open | 3.20 |
| Previous Close | 3.26 |
| Day's Range | 3.16 - 3.43 |
| 52-Week Range | 3.10 - 7.98 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 14.00(+315.43%) |
| Earnings Date | Sep 25, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About IVA
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
$IVA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IVA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IVA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IVA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IVA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IVA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IVA
| ETF | Est. Holding Size |
|---|---|
| SURISimplify Propel Opportunities ETF | $1.02M |
| GWXState Street SPDR S&P International Small Cap ETF | $396.61K |
| MEDIHarbor Health Care ETF (MEDI) | $110.83K |
| APIEActivePassive International Equity ETF | $45.11K |
| SPEUState Street SPDR Portfolio Europe ETF | $25.11K |
Estimated from each fund’s disclosed top holdings × AUM
IVA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IVA’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.